Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00663767 · ClinicalTrials.gov registry record · Phase 2

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

A Phase 2 study of Dental Pain, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
250
Enrollment target
2
Study locations

NCT00663767 is a Phase 2 study of Dental Pain that has completed, run by Pfizer. The registered enrollment target is 250 participants, above the 204-participant average among 6 other Dental Pain trials with a reported enrollment target (23% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00663767, a Phase 2 study of Dental Pain, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.

Conditions Studied

Interventions

  • DRUG ARRY-371797, p38 inhibitor; oral
  • DRUG Placebo; oral
  • DRUG Celecoxib, COX-2 inhibitor; oral

Study Locations (2)

Texas

  • PPD Phase I Clinic - Austin

Utah

  • Lifetree Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2008-04-07
Est. Completion 2008-06-20
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00663767

The ClinicalTrials.gov registry entry for NCT00663767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 204-participant average among 6 other Dental Pain trials with a reported enrollment target (23% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dental Pain appearing as the primary indexed condition, and to 3 interventions - of which ARRY-371797, p38 inhibitor; oral is the first listed.

NCT00663767 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT00663767 about?

NCT00663767 is a clinical study titled "A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction". This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.

What is the current status of trial NCT00663767?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2008-04-07. Estimated completion is 2008-06-20.

What conditions does trial NCT00663767 study?

This clinical trial studies the following conditions: Dental Pain.

What interventions are being tested in trial NCT00663767?

The interventions under investigation include: ARRY-371797, p38 inhibitor; oral (DRUG), Placebo; oral (DRUG), Celecoxib, COX-2 inhibitor; oral (DRUG).

Who is sponsoring clinical trial NCT00663767?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00663767 being conducted?

This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dental Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.